TACE (Transarterial Chemoembolization)
TACE (Transarterial Chemoembolization) is a minimally invasive interventional radiology procedure primarily used to treat liver cancers, especially hepatocellular carcinoma (primary liver cancer), and certain cancers that have spread to the liver. It involves delivering chemotherapy drugs directly into the artery supplying the tumor, followed by the injection of embolic agents that block the blood flow to the tumor. This targeted approach helps destroy cancer cells while minimizing the effect on surrounding healthy tissues. TACE is commonly recommended for patients who are not suitable candidates for surgery or as a bridging treatment before liver transplantation. The procedure is usually performed under local anesthesia with sedation, where a thin catheter is inserted through the groin or wrist artery and guided to the liver under imaging assistance. It is a minimally invasive procedure, typically completed within 1–3 hours, with a hospital stay of 1–3 days depending on the patient’s condition. Most patients may experience temporary fatigue, abdominal discomfort, nausea, fever, or loss of appetite for a few days after the procedure, but recovery is generally within 1–2 weeks. One of the major benefits of TACE is its ability to directly target liver tumors, control cancer progression, reduce tumor size, relieve symptoms, and improve survival outcomes in selected patients. Overall, TACE is considered a safe and effective treatment option for appropriately selected patients with liver cancer.











Appointment
Call
More